AbbVie Inc (ABBV)vsEvotec SE ADR (EVO)
ABBV
AbbVie Inc
$251.07
-0.23%
HEALTHCARE · Cap: $447.62B
EVO
Evotec SE ADR
$2.85
-5.72%
HEALTHCARE · Cap: $975.56M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 8332% more annual revenue ($62.82B vs $745.04M). ABBV leads profitability with a 5.8% profit margin vs -26.0%. ABBV appears more attractively valued with a PEG of 0.41. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
EVO
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.3%
Fair Value
$146.22
Current Price
$251.07
$104.85 premium
Intrinsic value data unavailable for EVO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -28.0% — below average capital efficiency
Revenue declined 21.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : EVO
The strongest argument for EVO centers on Price/Book. PEG of 1.42 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 123.6x leaves little room for execution misses.
Bear Case : EVO
The primary concerns for EVO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while EVO is a turnaround play — different risk/reward profiles.
EVO carries more volatility with a beta of 1.30 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 35/100) and 12.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Evotec SE ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evotec SE is a prominent global biotechnology company headquartered in Hamburg, Germany, specializing in delivering comprehensive drug discovery and development solutions to the pharmaceutical and biotech industries. The firm is distinguished by its collaborative strategy, forming partnerships with leading pharmaceutical entities and prestigious academic institutions to accelerate the progress of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline, Evotec is strategically positioned to leverage new opportunities within the biopharmaceutical sector, reaffirming its essential contribution to healthcare innovation and improved patient outcomes.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?